Clinical trials: COVID-19 ARDS
SARS-CoV 2 Pneumonia
Long Term Effects of Awake Prone Positioning in COVID-19 ICU Patients
Long term follow up of patients included in a randomized controlled trial evaluating awake prone positioning among patients suffering SARS-CoV2 pneumonia (NCT04358939)
- Trial name
- Long-termAPP (NCT06080737)
- Testing
- quality of life questionnaire
- Where
- France
- Volunteers
- 137 people
- Sponsor
- University Hospital, Tours
Covid19, COVID-19 Pneumonia
Efficacy and Safety of Antimicrobial Stewardship Intervention in Hospitalized COVID-19 Patients (COVASP)
COVID-19 is respiratory disease caused by the severe acute respiratory coronavirus 2 (SARS-CoV-2), a novel coronavirus which has spread rapidly across the world with over 149.9 million laboratory confirmed cases and over 3.1…
- Conditions
- Covid19, COVID-19 Pneumonia, COVID-19 Lower Respiratory Infection, COVID-19 Acute Respiratory Distress Syndrome
- Trial name
- COVASP (NCT04896866)
- Testing
- Antimicrobial stewardship prospective audit and feedback
- Where
- 3 sites in Canada
- Volunteers
- 833 people
- Sponsor
- University of Alberta
Covid19, SARS-CoV Infection
Steroids and Unfractionated Heparin in Critically Ill Patients With Pneumonia From COVID-19 Infection
SARS-CoV-2 infection seems to induce in most critical cases an excessive and aberrant hyper-inflammatory host immune response that is associated with a so-called "cytokine storm", moreover pro-thrombotic derangements of…
- Conditions
- Covid19, SARS-CoV Infection, Pneumonia, Viral, Coagulopathy
- Trial name
- STAUNCH-19 (NCT04528888)
- Testing
- Enoxaparin, Methylprednisolone, unfractionated heparin
- Where
- Italy
- Volunteers
- 210 people
- Sponsor
- Massimo Girardis
COVID-19, ARDS
Extracellular Vesicle Infusion Treatment for COVID-19 Associated ARDS
To evaluate the safety and efficacy of intravenous administration of bone marrow derived extracellular vesicles, ExoFlo, versus placebo as treatment for moderate-to-severe Acute Respiratory Distress Syndrome (ARDS) in patients…
- Trial name
- EXIT-COVID19 (NCT04493242)
- Testing
- ExoFlo, Intravenous normal saline
- Where
- 6 sites in United States
- Volunteers
- 102 people
- Sponsor
- Direct Biologics, LLC
COVID-19 Pneumonia, COVID-19 Respiratory Infection
Follow-up of Covid-19 Long Term Sequelae
The protocol, in accordance with the objectives of ORCHESTRA project - Work Package 2, aims at investigating the characteristics and determinants of COVID-19 long-term sequelae.
- Conditions
- COVID-19 Pneumonia, COVID-19 Respiratory Infection, COVID-19 Acute Bronchitis, COVID-19 Acute Respiratory Distress Syndrome
- Trial name
- NCT05097677
- Testing
- Not applicable (observational study)
- Where
- 7 sites in Belgium, France and 4 more
- Volunteers
- 7,599 people
- Sponsor
- Azienda Ospedaliera Universitaria Integrata Verona
Covid-19
Bicentric Study on the Use of ECMO-VV or VA for Severe ARDS Associated With Covid-19
Describes the cohort of patients receiving ECMO-VV or ECMO-VA in the management of severe ARDS refractory to SARS-CoV-2 in the Strasbourg and Louvain centres
- Trial name
- ECMO-SL-CoV-2 (NCT04446286)
- Where
- France
- Volunteers
- 50 people
- Sponsor
- University Hospital, Strasbourg, France
COVID-19 Acute Respiratory Distress Syndrome, Cytokine Release Syndrome
Safety and Effectiveness of Cyclosporin in the Management of COVID19 ARDS Patients in Alexandria University Hospital
The study to evaluate the effect of cyclosporine ( IL2 inhibitor and antiviral) verse standard care treatment on decrease ADRS, hyper inflammation, hypercytokinemia, and the mortality rate
- Conditions
- COVID-19 Acute Respiratory Distress Syndrome, Cytokine Release Syndrome, Pulmonary Fibrosis
- Trial name
- NCT04979884
- Testing
- cyclosporine
- Where
- Egypt
- Volunteers
- 66 people
- Sponsor
- Alexandria University
COVID-19 Acute Respiratory Distress Syndrome
Nigelle 5 in Prevention of Influanza
This study will be carried out by more than 30 liberal Tunisian doctors, who will submit according to the inclusion / exclusion criteria of people who will receive (free of charge) a capsule of the Nig5 product sublingually, each…
- Trial name
- NigCOV3 (NCT04989101)
- Testing
- Nigella
- Where
- Tunisia
- Volunteers
- 500 people, healthy volunteers welcome
- Sponsor
- Hôpital Universitaire Sahloul
COVID-19 Acute Respiratory Distress Syndrome, Cytokine Release Syndrome
Tazemetostat for the Treatment of Moderate to Severe COVID-19 Infection
The purpose of this study is to assess the safety and efficacy of repurposing tazemetostat for the treatment of Acute Respiratory Distress Syndrome (ARDS) or Systemic Cytokine Release Syndrome (SCRS) in COVID-19 patients.
- Trial name
- IST (NCT05018975)
- Testing
- Tazemetostat
- Volunteers
- healthy volunteers welcome
- Sponsor
- Loma Linda University
COVID-19, Organ Dysfunction Syndrome Sepsis
Mechanisms for Organ Dysfunction in Covid-19
The study aims to investigate organ dysfunction and biomarkers in patients with suspected or verified COVID-19 during intensive care at Uppsala University Hospital.
- Conditions
- COVID-19, Organ Dysfunction Syndrome Sepsis, Organ Dysfunction Syndrome, Multiple, Septic Shock
- Trial name
- UMODCOVID19 (NCT04316884)
- Where
- Sweden
- Volunteers
- 380 people
- Sponsor
- Uppsala University
COVID-19, Acute Respiratory Distress Syndrome
Umbilical Cord Tissue (UC) Derived Mesenchymal Stem Cells (MSCs) Versus Placebo to Treat Acute Pulmonary Inflammation Due to COVID-19
The purpose of this study is to demonstrate the safety of Umbilical Cord Tissue Derived Mesenchymal Stem Cells (UCMSCs) administered intravenously in patients with acute pulmonary inflammation due to COVID-19 with moderately…
- Conditions
- COVID-19, Acute Respiratory Distress Syndrome, Corona Virus Infection
- Trial name
- COVID-19 (NCT04490486)
- Testing
- UCMSCs
- Sponsor
- Joshua M Hare
Respiratory Distress Syndrome, Adult, COVID-19
Determine the Effects of Prone Positioning and NO in COVID-19 ARDS by EIT
We aims to investigate the effects of prone positioning and nitric oxide inhalation in adult patients who is diagnosed with COVID-19 associated acute respiratory distress syndrome by electrical impedance tomography.
- Trial name
- NCT05715762
- Testing
- prone postion, NO inhalation
- Where
- China
- Volunteers
- 20 people
- Sponsor
- Shanghai Zhongshan Hospital
COVID-19, Severe Respiratory Distress Syndrome
suPAR Michigan M2C2 Heterogeneity Validation Cohort Study
This is a retrospective, non interventional cohort study using stored plasma samples from appoximately 300 adults hospitalized with confirmed COVID 19.
- Conditions
- COVID-19, Severe Respiratory Distress Syndrome, Acute Respiratory Distress Syndrome
- Trial name
- NCT07466524
- Testing
- suPARnostic® TurbiLatex Assay on Roche cobas c501
- Where
- United States
- Volunteers
- 367 people
- Sponsor
- ViroGates A/S
Sedation Complication, Acute Respiratory Distress Syndrome Due to COVID-19
Assessment of Sedation Depth Using Processed EEG in ICU Patients With ARDS Receiving Neuromuscular Blockade: A Prospective Observational Study"
"In intensive care units, therapeutic paralysis has been a routine treatment method for many years in a select group of patients.
- Conditions
- Sedation Complication, Acute Respiratory Distress Syndrome Due to COVID-19, Anesthesia Awareness
- Trial name
- NCT06337877
- Testing
- Depth of sedation monitoring
- Where
- Turkey (Türkiye)
- Volunteers
- 52 people
- Sponsor
- Tepecik Training and Research Hospital
Critical COVID-19 With Respiratory Failure, Acute Respiratory Distress Syndrome (ARDS)
Intravenous Aviptadil for Critical COVID-19 With Respiratory Failure
Novel Corona Virus (SARS-CoV-2) is known to cause Respiratory Failure, which is the hallmark of Acute COVID-19, as defined by the new NIH/FDA classification.
- Conditions
- Critical COVID-19 With Respiratory Failure, Acute Respiratory Distress Syndrome (ARDS), Corona Virus Infection, Acute Lung Injury
- Trial name
- COVID-AIV (NCT04311697)
- Testing
- Aviptadil by intravenous infusion + standard of care, Normal Saline Infusion + standard of care
- Where
- 10 sites in United States
- Volunteers
- 203 people
- Sponsor
- APR Applied Pharma Research s.a.
COVID-19, Hypoxia
Administration of Intravenous Vitamin C in Novel Coronavirus Infection (COVID-19) and Decreased Oxygenation
Previous research has shown that high dose intravenous vitamin C (HDIVC) may benefit patients with sepsis, acute lung injury (ALI), and the acute respiratory distress syndrome (ARDS).
- Trial name
- AVoCaDO (NCT04357782)
- Testing
- L-ascorbic acid
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- Hunter Holmes Mcguire Veteran Affairs Medical Center
Acute Respiratory Distress Syndrome, Covid19
Safety of T Regulatory Cell Therapy in Subjects With COVID-19 Induced Acute Respiratory Distress Syndrome
This study is to evaluate the feasibility and safety of treatment with related donor Human Leukocyte Antigen (HLA) matched or haploidentical allogeneic T regulatory cells in patients with COVID 19 induced ARDS.
- Trial name
- NCT04737161
- Testing
- T regulatory cells
- Where
- United States
- Sponsor
- Stanford University
ARDS, Mechanical Ventilation
Continuous Flow Ventilation With the Ventijet System in Acute Respiratory Distress Syndrome: a First-in-Human Feasibility and Non-Inferiority Trial
This prospective, non-randomized, single-arm, proof-of-concept clinical trial evaluates the physiological performance and safety of the Ventijet System, a hybrid ventilation system based on continuous high-velocity gas flow.
- Conditions
- ARDS, Mechanical Ventilation, Hypoxemic Respiratory Failure
- Trial name
- Ventijet (NCT07121257)
- Testing
- VENTIJET system
- Where
- Spain
- Volunteers
- 14 people
- Sponsor
- Hospital del Mar
SARS-CoV 2, COVID
Inhaled ZYESAMI (Aviptadil Acetate) for Treatment of Severe COVID-19
Brief Summary: SARS-CoV-2 virus infection is known to cause Lung Injury that begins as dyspnea and exercise intolerance, but may rapidly progress to Critical COVID-19 with Respiratory Failure and the need for noninvasive or…
- Conditions
- SARS-CoV 2, COVID, ARDS, ALI
- Trial name
- AVICOVID-3 (NCT05137795)
- Testing
- ZYESAMI™ (aviptadil acetate)
- Sponsor
- APR Applied Pharma Research s.a.
Ards, Covid19
FX06 to Rescue Acute Respiratory Distress Syndrome During Covid-19 Pneumonia
Vascular leakage following endothelial injury, responsible for interstitial and alveolar edema, is a major feature of pathogen induced acute lung injury.
- Conditions
- Ards, Covid19, Pneumonia
- Trial name
- FX-COVID (NCT04618042)
- Testing
- FX06
- Where
- 3 sites in France
- Volunteers
- 50 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris